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Precision medicine to improve use of bleeding avoidance 
strategies and reduce bleeding in patients undergoing 
percutaneous coronary intervention: prospective cohort study 
before and after implementation of personalized bleeding risks
John A Spertus,1, 2 Carole Decker,1, 2 Elizabeth Gialde,1 Philip G Jones,1 Edward J McNulty,3 
Richard Bach,4 Adnan K Chhatriwalla1, 2
AbstrAct
ObjeCtive
To examine whether prospective bleeding risk 
estimates for patients undergoing percutaneous 
coronary intervention could improve the use of 
bleeding avoidance strategies and reduce bleeding.
Design
Prospective cohort study comparing the use of 
bleeding avoidance strategies and bleeding rates 
before and after implementation of prospective risk 
stratification for peri-procedural bleeding.
setting
Nine hospitals in the United States.
PartiCiPants
All patients undergoing percutaneous coronary 
intervention for indications other than primary 
reperfusion for ST elevation myocardial infarction.
Main OutCOMe Measures
Use of bleeding avoidance strategies, including 
bivalirudin, radial approach, and vascular closure 
devices, and peri-procedural bleeding rates, stratified 
by bleeding risk. Observed changes were adjusted for 
changes observed in a pool of 1135 hospitals without 
access to pre-procedural risk stratification. Hospital 
level and physician level variability in use of bleeding 
avoidance strategies was examined. 
results
In a comparison of 7408 pre-intervention procedures 
with 3529 post-intervention procedures, use of 
bleeding avoidance strategies within intervention sites 
increased with pre-procedural risk stratification (odds 
ratio 1.81, 95% confidence interval 1.44 to 2.27), 
particularly among higher risk patients (2.03, 1.58 to 
2.61; 1.41, 1.09 to 1.83 in low risk patients, after 
adjustment for control sites; P for interaction=0.05). 
Bleeding rates within intervention sites were 
significantly lower after implementation of risk 
stratification (1.0% v 1.7%; odds ratio 0.56, 0.40 to 
0.78; 0.62, 0.44 to 0.87, after adjustment); the 
reduction in bleeding was greatest in high risk 
patients. Marked variability in use of bleeding 
avoidance strategies was observed across sites and 
physicians, both before and after implementation.
COnClusiOns
Prospective provision of individualized bleeding risk 
estimates was associated with increased use of 
bleeding avoidance strategies and lower bleeding 
rates. Marked variability between providers highlights 
an important opportunity to improve the consistency, 




Most medical treatments are associated with heteroge-
neity of benefit; some patients benefit a great deal from 
treatment, whereas others do not.1 2 Observational stud-
ies show many examples of a “risk-treatment paradox,” 
in which patients at the highest risk (and with the great-
est potential to gain from treatment) are treated less 
often than those at lower risk and with less potential to 
benefit.3–10 These practice patterns are not patient cen-
tered and are intrinsically inefficient in terms of costs, 
safety, and outcomes. Developing methods to integrate 
individualized risk stratification within routine clinical 
care has the potential to remedy this paradoxical prac-
tice pattern by alerting clinicians to each patient’s 
potential benefits from treatment and enabling more 
patient centered, evidence based, efficient care with 
safer, better outcomes.11
The use of bleeding avoidance strategies at the time 
of percutaneous coronary intervention is a prototypical 
example of the risk-treatment paradox. Bleeding is one 
of the most common non-cardiac complications of per-
cutaneous coronary intervention and is associated with 
increased mortality, morbidity, and costs.12–19 It is also 
modifiable through the use of bleeding avoidance strat-
egies, such as bivalirudin, radial percutaneous coronary 
WhAt Is AlreAdy knoWn on thIs topIc
Bleeding is one of the most common complications of percutaneous coronary 
intervention (PCI)
Valid models to estimate patients’ risks of bleeding have been developed
Bleeding avoidance strategies can reduce bleeding but are paradoxically applied to 
patients with the lowest risk of bleeding, resulting in inefficient and less effective 
treatment than could be obtained by preferentially treating higher risk patients
WhAt thIs study Adds
After provision of patients’ individualized estimates of risk before PCI, bleeding 
avoidance strategies were preferentially increased in those at higher risk of 
bleeding and the odds of bleeding were reduced by 44%
Marked variability existed in how individual operators treated patients, on the basis 
of their risk of bleeding, both before and after the provision of patients’ bleeding 
risks
An opportunity exists to improve the consistency of bleeding avoidance 
management to further improve the safety of PCI
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intervention, and, potentially, vascular closure 
devices.20–25 Importantly, although the magnitude of 
bleeding reduction and bleeding related mortality are 
strongly associated with patients’ underlying risk of 
bleeding,19 22 bleeding avoidance strategies are para-
doxically used most often in patients at low risk of 
bleeding and least often in those at high risk.22
To improve use of bleeding avoidance strategies, and 
reduce percutaneous coronary intervention related 
bleeding, we implemented a novel method for prospec-
tively determining and informing physicians of 
patients’ bleeding risks by using a validated risk model 
developed by the American College of Cardiology’s 
National Cardiovascular Data Registry (NCDR) CathPCI 
Registry.26 Patients’ personalized risks were calculated 
with the Patient Risk Information Services Manager 
(ePRISM),27–29 which was designed to translate multi-
variable risk models, using each patient’s specific clin-
ical risk factors, at the point of care. As a vehicle to 
translate models to the clinical setting, ePRISM was 
designed to be seamlessly integrated within routine 
clinical workflow. In the setting of percutaneous coro-
nary intervention, ePRISM was used to generate per-
sonalized consent forms and replace sites’ traditional 
consent forms, where it has recently been shown to 
improve patients’ experience with care.30 It also created 
streamlined decision support tools that could be 
printed and given to physicians before the percutane-
ous coronary intervention procedure.
We did a pre/post-implementation study at nine large 
US percutaneous coronary intervention centers and 
evaluated changes in use of bleeding avoidance strate-
gies and bleeding outcomes, while correcting for con-
temporary trends among matched NCDR CathPCI 
hospitals that did not have access to the ePRISM tool. 
We hypothesized that prospective stratification of 
bleeding risk could improve the use of bleeding avoid-
ance strategies in higher risk patients and reduce bleed-
ing in patients undergoing percutaneous coronary 
intervention.
Methods
In this prospective cohort study, individualized bleeding 
risk estimates were incorporated into the informed con-
sent document for all patients undergoing non-emer-
gent coronary angiography (supplemental figure A) and 
possible percutaneous coronary intervention at nine US 
centers (Washington University, Saint Louis, MO; Integ-
ris Hospital, Oklahoma, OK; Yale University, New Haven, 
CT; Henry Ford Hospital, Detroit, MI; Baystate Medical 
Center, Springfield, MA; The Heart Hospital at Baylor, 
Plano, TX; Kaiser Hospital, San Francisco, CA; St John’s 
Hospital, Springfield, IL; Mayo Clinic, Rochester, MN). 
The pre-procedural risk models were generated using 
the ePRISM software platform (Health Outcomes Sci-
ences, Overland Park, KS), which was provided through 
grant funding to each center. We compared use of bleed-
ing avoidance strategies and bleeding rates before and 
after implementation of the personalized risk esti-
mates.28 29 Because the routine process of care was 
changed at each center to include the new personalized 
consent forms, randomization of individual patients 
was not feasible. To overcome the most important bias 
in pre-/post-intervention comparisons—namely, tempo-
ral trends in care that could account for observed 
changes in treatment and outcomes—we used an addi-
tional comparison of non-participating NCDR sites as 
concurrent controls. This study design (supplemental 
figure B) was endorsed by two peer reviewed study sec-
tions (American Heart Association and the National 
Heart Lung and Blood Institute), who provided funding 
for the study.
The implementation of ePRISM has been previously 
described,27 31 and a rolling enrollment of sites led to 
staggered start dates between March 24, 2010 and May 
5, 2011. Before implementation of the new consent pro-
cess, a study investigator (JAS) provided didactic educa-
tion about the bleeding risk model and data on the 
comparative effectiveness of bleeding avoidance strate-
gies in reducing bleeding. Within one to two months of 
implementation, an interventional cardiologist (AKC) 
provided additional information on strategies to reduce 
bleeding as a function of risk. We considered the period 
between the start of prospective risk stratification and 
the interventionalist’s visit to be a “break-in” period 
and excluded it from analysis. We did not provide 
bleeding avoidance strategy protocols to the sites, and 
each site was able to implement the tool as fit best 
within their practice.
Data from all percutaneous coronary interventions 
performed during the study period were available for 
analysis through access to each site’s CathPCI Registry 
data. The CathPCI Registry, sponsored by the American 
College of Cardiology Foundation and the Society for 
Cardiovascular Angiography and Interventions, col-
lects detailed clinical characteristics, treatments, and 
outcomes using standardized definitions (www.ncdr.
com/webncdr/cathpci/home/datacollection).
The pre-implementation period consisted of the 12 
months before implementation of prospective bleeding 
risk stratification at each site. The post-implementation 
period consisted of the time period after system activa-
tion and a physician site visit for didactic education on 
the methods and approach to risk stratification. Data 
collected in the “break-in” period between implementa-
tion and the physician site visit were excluded from 
analysis.
study population
During the study period, 218 physicians across the nine 
sites performed 22 066 percutaneous coronary interven-
tion procedures. Patients were excluded from analysis 
for the following reasons: ST elevation myocardial 
infarction or other emergent procedures for which 
insufficient time was available to provide the personal-
ized consent form (n=3895); repeat percutaneous coro-
nary intervention during the same hospital admission 
for which attribution of which procedure was associ-
ated with bleeding is difficult (n=268); procedures of 
unknown status (emergent or other; n=33); procedures 
for which the percutaneous coronary intervention oper-
ator was not documented (n=274); procedures during 
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the “break-in” period between implementation and the 
physician site visit (n=1470); and procedures in the 
post-implementation period for which a personalized 
consent with bleeding risk was not generated (n=3156; 
for example, a consent had already been signed at a 
referring institution, administrative error). We excluded 
an additional 2033 procedures from analysis owing 
to  non-overlapping propensity scores between pre- 
implementation and post-implementation groups 
(see below). This resulted in a final study cohort of 
10 937 percutaneous coronary intervention procedures 
(7408 before implementation and 3529 after implemen-
tation) performed by 137 physicians.
bleeding risk estimates
The previously validated CathPCI Registry bleeding risk 
model incorporates nine pre-procedural clinical vari-
ables (age, sex, previous heart failure, glomerular filtra-
tion rate, peripheral vascular disease, previous 
percutaneous coronary intervention, functional status, 
ST elevation myocardial infarction/non-ST elevation 
myocardial infarction, and cardiogenic shock; C statis-
tic=0.72).26 Patients were classified as having low (<1%), 
moderate (1–3%), or high (>3%) risk of bleeding. We 
selected these cut-off values a priori on the basis of pre-
vious publications.22 Because the physicians’ education 
components of the intervention encouraged use of 
bleeding avoidance strategies in patients at moderate 
or high risk for bleeding, the categorical analyses of 
bleeding outcomes and changes in bleeding avoidance 
strategy use are between patients with low and moder-
ate/high risk (<1% v ≥1%) for bleeding. We calculated 
these risk estimates retrospectively for the pre-imple-
mentation period by using NCDR data, but they were 
not available to the physician before percutaneous cor-
onary intervention.
Outcomes
Study outcomes included use of bleeding avoidance 
strategies and in-hospital, post-procedural bleeding 
rates. Bleeding avoidance strategies were analyzed 
individually and by use of any strategy. Use of bivaliru-
din was considered the most modifiable strategy, as 
radial approaches are very operator dependent (inter-
ventionalists tend to predominantly use or not use this 
access approach) and the benefits of vascular closure 
devices to prevent bleeding are controversial.32 Bleed-
ing events were prospectively collected and defined 
according to standard NCDR definitions (access site, 
retroperitoneal, gastrointestinal, genitourinary, or 
unknown bleeding within 72 hours after percutaneous 
coronary intervention, associated with a drop in hemo-
globin of ≥3 g/dL or requiring transfusion, procedural 
intervention, or surgery).26
statistical analyses
To account for contemporary trends in use of bleeding 
avoidance strategies and bleeding incidence, we 
matched the nine study sites to control hospitals 
selected from among the 1135 CathPCI Registry sites not 
participating in this study. Hospitals were matched on 
annual percutaneous coronary intervention volume, 
teaching status, and the physicians’ average pre-ePRISM 
rate for each outcome. Given the number of  outcomes, 
we could not match intervention sites with controls on 
the pre-procedural rates of all five outcomes (bleeding, 
bivalirudin use, closure device use, radial access, and 
any bleeding avoidance strategy use), so we did separate 
matches for each outcome. To reduce the effects of 
 measurement error and sampling variation among the 
 specific control hospitals selected, we used full optimal 
matching to match as many controls as possible to each 
study site. Between 130 and 178 control hospitals were 
matched, depending on the outcome. We ensured 
 balance between study and matched control hospitals 
by calculating standardized differences, which were all 
less than 10% for each variable within each outcome 
analysis (supplemental table A).
To adjust for differences in patients’ and procedural 
characteristics before and after ePRISM implementation, 
as well as between study and control sites, we calculated 
multiple group propensity scores. This enabled us to 
adjust simultaneously for a myriad of patients’ charac-
teristics so that the differences in treatment and out-
comes were attributable to the intervention rather than 
to the types of patients treated in the different time peri-
ods. To do this, we constructed a multinomial logistic 
regression model predicting membership in each of the 
four “treatment” groups (study v control×pre- v  post-
ePRISM implementation) on the basis of 31 demographic, 
clinical, and procedural variables (table 1). From this 
model, we obtained three propensity scores estimating 
the probability of membership in each of three groups 
compared with the reference group of study sites before 
implementation of ePRISM. We assessed covariate bal-
ance by comparing propensity adjusted standardized 
differences between patients in the pre-intervention and 
post-intervention groups (<10% indicates good balance). 
Overlap of propensity score distributions among the four 
groups was good for all scores. We included these scores 
as covariates in the outcome models.
The primary unit of analysis in this study was the per-
cutaneous coronary intervention physician operator. We 
used hierarchical logistic regression models to assess 
the effect of exposure to ePRISM on physicians’ change 
in use of bleeding avoidance strategies and the inci-
dence of post-procedural bleeding, corrected for concur-
rent trends among control hospitals. Models included a 
fixed effect for study phase (before v after ePRISM imple-
mentation, centered within physician), physician level 
random intercepts and random effects for study phase, 
a fixed effect for study versus control hospital groups, a 
study phase-by-group interaction term, and adjustment 
for hospital matched sets and the three logit propensity 
scores. We quantified the effect of ePRISM as the relative 
difference in odds ratio for study phase between study 
and control hospitals. In addition, among the nine study 
sites, we evaluated variability in use of bleeding avoid-
ance strategies by physician with median odds ratios, 
which estimate the relative difference in use between 
two randomly selected physicians or hospitals for “iden-
tical” patients with the same covariates.
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Finally, we repeated the above analyses, augmenting 
the models with terms for bleeding risk and ePRISM-by-
risk interactions, to examine whether greater changes 
in treatment or benefit occurred among higher risk 
patients. We did separate analyses incorporating 
bleeding risk as a categorical (low v moderate/high) or 
continuous variable. Among the nine study sites, we 
derived variability in physicians’ use of bleeding avoid-
ance strategies as a function of bleeding risk both 
before and after implementation of ePRISM from the 
estimated random effects from the model incorporating 
bleeding risk as a continuous variable. We also repeated 
these approaches for other anticoagulation and anti-
platelet regimens, including unfractionated heparin, 
low molecular weight heparin, glycoprotein IIb/IIIa 
inhibitors, and thienopyridine use (both clopidogrel 
and prasugrel). We also did an exploratory descriptive 
analysis to assess the effect of pre-procedural risk strat-
ification on in-hospital mortality, as recorded in the 
NCDR registry, among the intervention sites. We used 
SAS 9.3 and R version 2.15.0 for all analyses.33 All 
hypothesis tests were two tailed and evaluated at a sig-
nificance level of 0.05.
results
The mean “break-in” period between implementation 
of pre-procedural risk stratification and the physician 
site visit was 2.1 months, and the mean study duration 
after the physician site visit was 9.4 months (supple-
mental table B). The final study cohort consisted of 
10 937 percutaneous coronary intervention procedures 
(7408 before implementation and 3529 after implemen-
tation) by 137 physicians. Table 1 shows patients’ base-
line demographic and clinical characteristics. 
Estimated bleeding risks were similar between the two 
groups. After propensity adjustment, all patients’ and 
procedural characteristics were well balanced (stan-
dardized differences 0–28% before adjustment, 0–7% 
after; supplemental table A).
Processes of care to mitigate bleeding
To understand the effect of pre-procedural risk stratifi-
cation on the use of bleeding avoidance strategies, we 
compared the observed changes at the intervention 
sites overall, and stratified by bleeding risk, and 
adjusted these observations for changes in bleeding 
avoidance strategy use at the control sites. Overall 
bleeding avoidance strategy use (table 2) increased 
from 81.4% to 88.7% after implementation (odds ratio 
1.81, 95% confidence interval 1.44 to 2.27; P<0.001). The 
increase was significantly greater in patients at high 
risk of bleeding (odds ratio 2.03 v 1.48 for low risk 
patients; P=0.05 for interaction). After correction for 
contemporary trends, the effect of pre-procedural risk 
stratification on the use of bleeding avoidance strate-
gies was of borderline statistical significance (cor-
rected odds ratio 1.23, 0.98 to 1.56) across all patients 
but significantly greater in patients at high risk for 
bleeding (1.41, 1.09 to 1.83; P=0.008). When we exam-
ined individual bleeding avoidance strategies, the 
availability of pre-procedural bleeding risk estimates 
was associated with similar overall use of bivalirudin 
(odds ratio 1.18, 0.93 to 1.48) but a change in practice 
that favored its use in high risk patients (1.36, 1.05 to 
1.75) over low risk patients (0.92, 0.69 to 1.24; P value 
for interaction=0.03). When we adjusted for control 
hospitals, we found no overall difference in bivalirudin 









Mean (SD) age, years 65.7 (11.6) 66.2 (11.5) 0.043
Male sex 5158 (69.6) 2504 (71.0)
Non-white ethnicity 886 (12.0) 409 (11.6) 0.575
No insurance 189 (2.6) 64 (1.8) 0.016
Admission source: <0.001
 Emergency department 1158 (15.6) 360 (10.2)
 Transfer in from another acute care facility 2368 (32.0) 891 (25.2)
 Other 3868 (52.2) 2275 (64.5)
Mean (SD) body mass index, kg/m2 30.1 (7.4) 30.3 (8.4) 0.295
Family history of premature coronary artery disease 2377 (32.1) 1089 (30.9) 0.178
Dyslipidemia 6582 (88.8) 3175 (90.0) 0.091
Hypertension 6373 (86.0) 3053 (86.5) 0.492
Diabetes 2679 (36.2) 1265 (35.8) 0.728
Previous myocardial infarction 2643 (35.7) 1346 (38.1) 0.012
Previous PCI 3209 (43.3) 1566 (44.4) 0.286
Previous coronary artery bypass graft 1693 (22.9) 863 (24.5) 0.064
Peripheral arterial disease 988 (13.3) 567 (16.1) <0.001
Cerebrovascular disease 976 (13.2) 480 (13.6) 0.539
Chronic heart failure 1072 (14.5) 549 (15.6) 0.142
Previous valve surgery/procedure 161 (2.2) 65 (1.8) 0.244
Chronic lung disease 950 (12.8) 511 (14.5) 0.017
On dialysis 207 (2.8) 99 (2.8) 0.974
Mean (SD) glomerular filtration rate, mL/min/1.73 m2 76.1 (27.4) 75.3 (26.0) 0.147
Mean (SD) pre-procedure hemoglobin, g/dL 13.3 (1.8) 13.4 (1.8) 0.014
Heart failure in previous 2 weeks 632 (8.5) 324 (9.2) 0.278
Cardiomyopathy or left ventricular systolic dysfunction 591 (8.0) 326 (9.2) 0.027
Cardiogenic shock in previous 24 hours 16 (0.2) 6 (0.2) 0.615
Cardiac arrest in previous 24 hours 23 (0.3) 9 (0.3) 0.615
Stress or imaging studies 2956 (39.9) 1618 (45.8) <0.001
Coronary artery disease presentation: <0.001
 Asymptomatic 817 (11.0) 385 (10.9)
 Symptom unlikely to be ischemic 73 (1.0) 38 (1.1)
 Stable angina 1565 (21.1) 762 (21.6)
 Unstable angina 3083 (41.6) 1633 (46.3)
 NSTEMI 1867 (25.2) 711 (20.1)
Anginal classification in previous 2 weeks: (n=7390) (n=3524) 0.136
 No symptoms 871 (11.8) 397 (11.3)
 CCS class I 249 (3.4) 108 (3.1)
 CCS class II 1465 (19.8) 763 (21.7)
 CCS class III 2353 (31.8) 1140 (32.3)
 CCS class IV 2452 (33.2) 1116 (31.7)
PCI status: <0.001
 Elective 3322 (44.8) 1836 (52.0)
 Urgent 4086 (55.2) 1693 (48.0)
PCI indication: <0.001
 High risk NSTEMI or unstable angina 4106 (55.4) 1796 (50.9)
 Staged PCI 372 (5.0) 181 (5.1)
 Other 2930 (39.6) 1552 (44.0)
Bleeding risk: (n=7143) (n=3415) 0.760
 Low (0 to <0.01) 2237 (31.3) 1047 (30.7)
 Moderate (0.01 to <0.03) 3523 (49.3) 1708 (50.0)
 High (≥0.03) 1383 (19.4) 660 (19.3)
CCS=Canadian Cardiovascular Society; NSTEMI=non-ST elevation myocardial infarction;
PCI=percutaneous coronary intervention.
*Without bleeding risk estimates.
†With individual bleeding risk estimates.
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use in high risk patients but decreased use in lower risk 
patients (odds ratio 0.73, 0.54 to 0.99; P=0.04). We 
found no significant changes in use of vascular closure 
devices within intervention sites or between interven-
tion and control sites. Although use of radial access 
increased within the intervention sites, these changes 
were similar to those at control sites and did not vary 
by bleeding risk categories.
Analyses incorporating risk of bleeding as a continu-
ous variable (supplemental figure C) showed significant 
increases in use of bleeding avoidance strategies after 
the availability of pre-procedural bleeding risk esti-
mates, although interactions between bleeding avoid-
ance strategy use and bleeding risk were not statistically 
significant. Other anticoagulation strategies (supple-
mental table C) also varied after the intervention, includ-
ing less use of low molecular weight heparin (overall 
odds ratio 0.62, 0.52 to 0.75; adjusted odds ratio 0.71, 0.59 
to 0.86, with no significant interaction by bleeding risk 
group) and less use of glycoprotein IIb/IIIa inhibitors 
(0.66, 0.55 to 0.79, with no interaction by bleeding risk 
group and no difference after adjustment for contempo-
rary practice in control sites: 0.91, 0.75 to 1.10). We 
observed no significant differences in the use of unfrac-
tionated heparin or thienopyridines (either clopidogrel 
or prasugrel) after pre-procedural risk stratification once 
we adjusted for changes in hospitals without access to 
pre-procedural bleeding risk estimates.
bleeding outcomes
Table 2 summarizes the effect of pre-procedural bleed-
ing risk estimates on bleeding. Bleeding complications 
decreased from 1.7% to 1.0% after implementation 
(odds ratio 0.56, 0.40 to 0.78; P<0.001), and this effect 
persisted after correction for contemporary trends (dif-
ference between differences 0.56 v 0.91, P<0.001; cor-
rected odds ratio 0.62, 0.44 to 0.87, P=0.006). Bleeding 
complications decreased significantly at intervention 
sites, compared with control sites, for patients at high 
risk of bleeding (odds ratio 0.65, 0.45 to 0.94; P=0.02) 
but not among patients at low risk of bleeding (0.51, 
0.21 to 1.20; P=0.12). Analyses incorporating risk of 
bleeding as a continuous variable (fig 1) suggested a 
greater absolute decrease in bleeding rate as bleeding 
risk increased. In contrast to the beneficial effects of 
pre-procedural risk stratification on bleeding, we 
observed no differences in in-hospital mortality 
among the intervention sites (0.37% pre-ePRISM v 
0.41% post-ePRISM; P=0.62).
Hospital and physician variability
Significant hospital and physician level variability in 
BAS use was present. In the post-implementation 
period, use of bleeding avoidance strategies ranged 
from 31% to 98%, bivalirudin use ranged from 1% to 
96%, vascular closure device use ranged from 3% to 
70%, and radial access ranged from 1% to 51% across 
hospitals. The effect of pre-procedural bleeding risk 
estimates on bleeding avoidance strategy use varied 
widely across hospitals (table 3), with hospital spe-
cific odds ratios for the use of any strategy ranging 
from 0.49 to 2.65 (P=0.006 for differences by hospital), 
although the effect of ePRISM on bleeding avoidance 
strategy use was greater than 1.0 in seven of nine 




odds ratio (95% Ci)





rate Odds ratio (95% Ci) P value
PrisM×risk 
interaction 
P value Odds ratio (95% Ci) P value
Outcomes—peri-procedural bleeding
Post-PCI bleeding:
 Overall 1.7% 1.0% 0.56 (0.40 to 0.78) <0.001 0.71 0.91 (0.84 to 0.98) 0.62 (0.44 to 0.87) 0.006
 Low bleeding risk 0.7% 0.3% 0.46 (0.20 to 1.06) 0.07 0.91 (0.74 to 1.11) 0.51 (0.21 to 1.20) 0.12
 Moderate/high bleeding risk 2.1% 1.3% 0.59 (0.41 to 0.85) 0.004 0.90 (0.83 to 0.98) 0.65 (0.45 to 0.94) 0.02
Processes of care—bleeding avoidance strategies
Any strategy:
 Overall 81.4% 88.7% 1.81 (1.44 to 2.27) <0.001 0.05 1.46 (1.38 to 1.55) 1.23 (0.98 to 1.56) 0.08
 Low bleeding risk 85.9% 90.0% 1.48 (1.08 to 2.04) 0.02 1.50 (1.39 to 1.62) 0.99 (0.71 to 1.37) 0.94
 Moderate/high bleeding risk 78.7% 88.3% 2.03 (1.58 to 2.61) <0.001 1.44 (1.35 to 1.53) 1.41 (1.09 to 1.83) 0.008
Bivalirudin:
 Overall 48.6% 52.6% 1.18 (0.93 to 1.48) 0.17 0.03 1.28 (1.21 to 1.36) 0.92 (0.72 to 1.16) 0.47
 Low bleeding risk 51.5% 49.6% 0.92 (0.69 to 1.24) 0.61 1.27 (1.18 to 1.36) 0.73 (0.54 to 0.99) 0.04
 Moderate/high bleeding risk 47.9% 55.5% 1.36 (1.05 to 1.75) 0.02 1.29 (1.31 to 1.27) 1.05 (0.81 to 1.37) 0.70
Closure device:
 Overall 31.2% 28.9% 0.90 (0.73 to 1.10) 0.30 0.16 0.94 (0.89 to 0.99) 0.96 (0.77 to 1.18) 0.67
 Low bleeding risk 37.4% 33.4% 0.84 (0.64 to 1.10) 0.20 0.90 (0.84 to 0.96) 0.94 (0.71 to 1.24) 0.65
 Moderate/high bleeding risk 29.4% 28.6% 0.96 (0.77 to 1.20) 0.73 0.95 (0.89 to 1.00) 1.02 (0.81 to 1.28) 0.88
Radial access*:
 Overall 4.7% 10.7% 2.45 (1.84 to 3.26) <0.001 0.46 2.26 (2.03 to 2.51) 1.09 (0.80 to 1.47) 0.60
 Low bleeding risk 5.6% 14.2% 2.77 (1.90 to 4.02) <0.001 2.54 (2.22 to 2.91) 1.09 (0.73 to 1.62) 0.68
 Moderate/high bleeding risk 4.5% 9.8% 2.32 (1.72 to 3.14) <0.001 2.36 (2.11 to 2.63) 0.99 (0.72 to 1.36) 0.93
*Among physicians performing at least one radial procedure before implementation of PRISM.
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 hospitals, suggesting that all but two hospitals 
increased their use of such strategies after being pro-
vided with pre-procedural estimates of patients’ 
bleeding risk. Within hospitals, we also saw substan-
tial variability in bleeding avoidance strategy use by 
physicians at each hospital (table 4). The median 
odds ratio for any use of any strategy, after adjust-
ment for between hospital differences, was 4.1 when 
the personalized consents were used, indicating a 
fourfold difference in the probability of any bleeding 
avoidance strategy use between two randomly 
selected physicians at the same hospital treating 
patients with identical bleeding risk and other clini-
cal characteristics. We observed similar variation for 
each individual strategy, with bivalirudin use show-
ing the greatest variability. Figure 2 shows the use of 
bivalirudin as a function of patients’ bleeding risks, 
before and after pre-procedural risk stratification. 
This figure emphasizes the wide variability across 
physicians, even after personalized estimates of 
bleeding were provided. Some physicians never used 
bivalirudin, even among the patients at highest risk 
for bleeding, whereas others used it in all of their high 
risk patients. Physician level performance for other 
strategies are shown in supplemental figure D.
discussion
To our knowledge, this is the first demonstration that 
precision medicine, delivered through pre-procedural 
risk stratification, can improve the safety of medical care 
by supporting tailored treatment in patients at the great-
est risk for adverse outcomes. In this before/after study at 
nine US percutaneous coronary intervention centers, we 
sought to overcome a well documented risk-treatment 
paradox in healthcare delivery by prospectively provid-
ing personalized estimates of bleeding risk for patients 
undergoing percutaneous coronary intervention. This 
intervention was associated with increased use of bleed-
ing avoidance strategies overall, with a greater use in 
high risk patients (odds ratio 1.41) after adjustment for 
contemporary trends in bleeding management. The only 
other change in anticoagulation regimens observed at 
the intervention sites, compared with control sites, was a 
lower use of low molecular weight heparins, which have 
been associated with less bleeding and may have dimin-
ished the observed differences in bleeding between inter-
vention and control sites. Most importantly, the overall 
bleeding rates improved significantly more at the inter-
vention sites after prospective risk stratification than was 
observed at other matched hospitals participating in the 
NCDR registry (reduction in odds of bleeding at interven-
tion sites 44% v 9% at control sites). These findings 
extend our previous experience at a single institution to 
support the generalizability of this approach.34
implications of findings
This study highlights the potential value of risk models 
to improve care. Although risk adjusted benchmarking 
of performance can enable hospitals to identify whether 




























Fig 1 | unadjusted rates of bleeding before and after 
ePrisM implementation, as a function of bleeding risk. 
PCi=percutaneous coronary intervention
table 3 | variation in bleeding avoidance strategy (bas) use and effect of personalized 
bleeding risk estimates across hospitals
bleeding avoidance strategy
range in bas use range in effect of PrisM
Pre-PrisM Post-PrisM Odds ratios P value
Any strategy 13–98% 31–98% 0.49–2.65 0.006
Bivalirudin 1–95% 1–96% 0.63–2.20 0.20
Closure device 0.2–80% 3–70% 0.48–18.09 <0.001
Radial access 1–14% 1–51% 0.24–4.02 0.07
table 4 | variation in bleeding avoidance strategy use and effect of personalized 
bleeding risk estimates across physicians
bleeding avoidance strategy
Median odds ratios across all 
hospitals
Median odds ratios within 
hospitals
Pre-PrisM Post-PrisM Pre-PrisM Post-PrisM
Any strategy 9.4 7.8 3.7 4.1
Bivalirudin 11.0 11.3 3.7 4.5
Closure device 7.9 6.3 3.5 4.2
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Fig 2 | individual physicians’ variability in use of 
bivalirudin, as a function of bleeding risk, before and after 
PrisM. each line represents a physician in the study
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peers, we are unaware of any examples in which these 
models have been prospectively used to improve medi-
cal decision making. In the case of percutaneous coro-
nary intervention related bleeding, the CathPCI Registry 
data enabled researchers to create a risk model to pre-
dict bleeding,26 determine that bleeding avoidance 
strategies were preferentially used in patients at the 
lowest risk and with the least potential to benefit,22 and 
prospectively use that model to support more efficient, 
evidence based medical decision making and safer 
care. Many additional opportunities exist to update the 
risk models with emerging risk factors and extend this 
concept to other medical disciplines.35
This study also highlights extraordinary variability in 
care by both hospitals and physicians within hospitals. 
For example, the use of bivalirudin varied from 1% to 
95% across the nine centers in this study, with an 11-fold 
difference in the likelihood that two patients with identi-
cal characteristics treated by one random physician ver-
sus another would be treated with the drug. Even within 
the same hospital, a fourfold variation in bivalirudin use 
existed across providers, after adjustment for risk of 
bleeding and patients’ other characteristics. For exam-
ple, few people would argue that a patient with a very 
high, 10% risk of bleeding should not be treated with at 
least one bleeding avoidance strategy. In this study, we 
found that the likelihood of such a patient receiving any 
bleeding avoidance strategy ranged from 1% to 100%, 
depending on which interventionalist performed the 
procedure. Decreasing such variability in care based on 
physicians’ preferences, rather than patients’ benefits, 
represents an important opportunity to improve quality 
and outcomes. Given that the provision of prospective, 
individualized bleeding risk estimates had little effect on 
the observed variability in care, we believe that future 
efforts to support more consistent care may require 
implementation of clear protocols for optimal use of 
bleeding avoidance strategies as a function of bleeding 
risk, feedback reports on protocol adherence, and hold-
ing physicians accountable for their practice patterns.36
limitations of study
Our findings should be interpreted in the context of sev-
eral potential limitations. Firstly, this was a non-ran-
domized study with a before/after design. Because we 
changed the processes of obtaining informed consent, 
we could not randomize individual patients. A cluster 
randomized study design would have more definitively 
compared the effect of pre-procedural risk stratification 
on care and outcomes. Nevertheless, we were able to 
leverage the same data collection infrastructure at more 
than 1100 hospitals to document a significantly greater 
reduction in bleeding compared with contemporary 
trends. We were also able to use propensity models to 
ensure that patients in the pre-intervention phase were 
similar to those in the post-intervention time period. 
Secondly, the inclusion of nine sites limits the general-
izability of the findings to other institutions. Our find-
ings are also not generalizable to ST elevation 
myocardial infarction or emergent patients, as these 
emergency cases were excluded from our study. 
 However, the lessons learnt from this effort, particularly 
our belief in the importance of having established pro-
tocols and feedback, could potentially lead to more suc-
cessful future implementations.
A third limitation is that the optimal management of 
anticoagulation and antiplatelet treatment at the time of 
percutaneous coronary intervention is complex,37 with 
both oral (for example, clopidogrel,  aspirin) and intra-
venous (glycoprotein IIb/IIIa)  antiplatelet agents and a 
range of anticoagulants (bivalirudin, unfractionated 
and low molecular weight heparin) used in various com-
binations by different operators. We were unable to attri-
bute the reduction in bleeding solely to the observed 
changes in use of bleeding avoidance strategies. How-
ever, this does not detract from the importance of our 
finding that prospective risk stratification was associ-
ated with improved bleeding outcomes for patients 
undergoing percutaneous coronary intervention, how-
ever it was achieved. An additional concern might be the 
recently announced results of the HEAT PPCI study, in 
which bivalirudin did not result in less bleeding than 
heparin alone.38 We excluded primary percutaneous cor-
onary intervention from our analyses, and our results 
should not be affected by this new information. A fur-
ther potential concern is the short time of observation 
after pre-procedural risk stratification was introduced 
and that physicians might take a longer time to incorpo-
rate such information into their practice patterns, some-
thing that would have led to underestimation of the 
potential benefits of this approach. Finally, the bleeding 
events were not  independently adjudicated, with reli-
ance on the NCDR data collection infrastructure, and we 
were not able to adjudicate ischemic complications that 
may have been affected by changes in antithrombotic 
treatment. We also did not have long term outcomes 
available, and nor were we able to compare the accuracy 
of bleeding events in NCDR between our nine centers 
and the rest of the NCDR. Future work should attempt to 
assess these outcomes more definitely.
The Institute of Medicine has challenged US healthcare 
to be more patient centered, evidence based, and effi-
cient, as well as safer.11 We have previously reported that 
the enhanced informed consent documents generated by 
the personalized consents improved patients’ experi-
ences with consent to percutaneous coronary interven-
tion.39 In this study, we have shown that prospective, 
individualized bleeding risk estimates were associated 
with more appropriate use of bleeding avoidance strate-
gies and significantly lower bleeding rates. Nevertheless, 
the variability of care observed in this study suggests an 
important opportunity to further improve the safety and 
quality of percutaneous coronary intervention care.
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